Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

Summary

Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 15 April 2013

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 15 April 2013

   Introduced

   Introduced in House

   Source: IntroReferral

3. 15 April 2013

   Introduced

   Introduced in House

   Source: IntroReferral

4. 19 April 2013

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 15 April 2013 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 15 April 2013

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 15 April 2013

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 15 April 2013

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Rogers, Harold [R-KY-5] · R · Sponsor
• Rep. Keating, William R. [D-MA-9] · D · Sponsor
• Rep. Wolf, Frank R. [R-VA-10] · R · Sponsor
• Rep. Rahall, Nick J., II [D-WV-3] · D · Sponsor
• Rep. Grimm, Michael G. [R-NY-11] · R · Sponsor
• Rep. Lynch, Stephen F. [D-MA-8] · D · Sponsor
• Rep. Tierney, John F. [D-MA-6] · D · Sponsor
• Rep. Aderholt, Robert B. [R-AL-4] · R · Sponsor
• · hsif00 · Standing

Related records

• related to ← A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.